Insulin and Glucagon: Blood Sugar's Peptide Pair
Pancreatic Peptide Hormones
70 mg/dL
The difference between the upper and lower bounds of normal fasting blood glucose, a range maintained by the constant interplay of insulin and glucagon.
American Diabetes Association, Diabetes Care, 2024
American Diabetes Association, Diabetes Care, 2024
View as imageA healthy human body keeps blood glucose between approximately 70 and 140 mg/dL across an enormous range of conditions: fasting, feasting, sprinting, sleeping. Two peptide hormones produced by neighboring cells in the pancreatic islets of Langerhans make this possible. Insulin, a 51-amino-acid peptide from beta cells, drives glucose out of the blood and into cells. Glucagon, a 29-amino-acid peptide from alpha cells, pulls glucose back into the blood from liver stores. The pillar article on amylin (IAPP) covers the third major pancreatic peptide. This article focuses on the two that define the glucose regulation system, how they work at the molecular level, and what happens when the balance breaks down. Related articles cover C-peptide as a biomarker and pancreatic polypeptide.
Key Takeaways
- Insulin binds to tyrosine kinase receptors on muscle, liver, and fat cells, triggering GLUT4 transporter translocation that moves glucose from blood into cells within minutes
- Glucagon activates hepatic glycogenolysis and gluconeogenesis through cAMP-PKA signaling, capable of raising blood glucose by 30 to 60 mg/dL within 15 minutes of release
- The insulin-to-glucagon ratio, not the absolute level of either hormone alone, determines whether the liver produces or stores glucose at any given moment
- Proglucagon, the precursor peptide, generates both glucagon (in alpha cells) and GLP-1 (in intestinal L-cells), linking pancreatic and gut hormone systems through a single gene (Lafferty et al., 2021)
- Tirzepatide, a dual GIP/GLP-1 agonist, achieved normoglycemia (HbA1c below 5.7%) in 23.0% of type 2 diabetes patients in trials, demonstrating how targeting the incretin axis can restore near-normal glucose regulation (Popovic et al., 2024)
- Type 1 diabetes destroys beta cells but leaves alpha cells intact, creating a state of absolute insulin deficiency with dysregulated glucagon release that worsens glucose volatility
How Insulin Works: From Beta Cell to Glucose Transporter
Insulin is synthesized as preproinsulin, a single polypeptide chain. The endoplasmic reticulum cleaves the signal peptide to produce proinsulin, which folds into its three-dimensional structure and forms two disulfide bonds. Proteolytic enzymes then cut the C-peptide connecting segment, releasing mature insulin (an A-chain of 21 amino acids linked to a B-chain of 30 amino acids) and free C-peptide in equimolar amounts.
Beta cells store insulin in dense-core granules and release it in two phases. The first phase is a rapid burst lasting 5 to 10 minutes, triggered when blood glucose enters beta cells through GLUT2 transporters, is metabolized to produce ATP, and the rising ATP/ADP ratio closes potassium channels. This depolarizes the cell membrane, opens voltage-gated calcium channels, and calcium influx triggers granule exocytosis. The second phase is a sustained, slower release that continues as long as glucose remains elevated.
Once in the bloodstream, insulin binds to the insulin receptor, a transmembrane tyrosine kinase. Receptor activation triggers a phosphorylation cascade through insulin receptor substrate (IRS) proteins and phosphoinositide 3-kinase (PI3K). The downstream effect in muscle and adipose tissue is translocation of GLUT4 glucose transporters from intracellular vesicles to the cell surface. Each GLUT4 transporter can move approximately 10,000 glucose molecules per second across the membrane.
In the liver, insulin has different effects. Rather than GLUT4 translocation (hepatocytes use GLUT2, which is always present at the membrane), insulin activates glycogen synthase to convert glucose into glycogen for storage. It simultaneously suppresses glucose-6-phosphatase, the enzyme that releases glucose back into blood. The net result: glucose flows into cells and stays there.
How Glucagon Works: The Counter-Regulatory Response
Glucagon is the primary defense against hypoglycemia. When blood glucose drops below approximately 70 mg/dL, alpha cells in the pancreatic islets release glucagon into the portal vein, delivering it directly to the liver at high concentrations.
Glucagon binds to the glucagon receptor on hepatocytes, a G-protein coupled receptor that activates adenylyl cyclase. This raises intracellular cyclic AMP (cAMP), which activates protein kinase A (PKA). PKA phosphorylates glycogen phosphorylase, initiating glycogenolysis, the breakdown of stored glycogen into glucose. This is the fastest mechanism: the liver can release glucose within minutes of glucagon binding.
When glycogen stores are depleted (after approximately 24 hours of fasting), glucagon shifts to promoting gluconeogenesis, the synthesis of new glucose from non-carbohydrate precursors including lactate, glycerol, and amino acids. Glucagon activates the transcription factor CREB (cAMP response element-binding protein), which upregulates expression of gluconeogenic enzymes including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase.[1]
Glucagon secretion is regulated by multiple signals beyond glucose itself. Insulin from neighboring beta cells directly suppresses alpha cell glucagon release through paracrine signaling within the islet. Somatostatin from delta cells provides additional inhibitory control. From outside the pancreas, GLP-1 suppresses glucagon release while simultaneously enhancing insulin secretion, creating a coordinated post-meal response.[1]
The Insulin-to-Glucagon Ratio: Why Balance Matters More Than Levels
The liver does not respond to insulin or glucagon in isolation. It responds to the ratio between them. A high insulin-to-glucagon ratio signals the fed state: the liver stores glucose as glycogen, synthesizes fatty acids, and builds proteins. A low ratio signals fasting: the liver releases glucose, breaks down fat, and produces ketone bodies.
This ratio shifts dramatically across the day. After a carbohydrate-rich meal, insulin may rise 5-fold to 10-fold while glucagon drops, pushing the ratio strongly toward storage. During an overnight fast, insulin falls and glucagon rises, shifting the ratio toward glucose production. During intense exercise, the ratio can drop sharply as glucagon increases and insulin decreases, ensuring working muscles have access to glucose.
In type 2 diabetes, both sides of this ratio malfunction. Beta cells produce insufficient insulin or peripheral tissues resist its effects (insulin resistance). Alpha cells, meanwhile, fail to suppress glucagon release appropriately after meals, producing what researchers call "bihormonal failure." The result is simultaneously too much hepatic glucose output (from unsuppressed glucagon) and too little peripheral glucose uptake (from inadequate insulin action). Borer (2014) described this bihormonal dysfunction as a key driver of hyperglycemia, noting that the counterregulatory balance involves not just insulin and glucagon but also leptin and other metabolic peptides.[2]
Proglucagon: One Gene, Multiple Peptide Products
Glucagon is not an isolated product. It comes from proglucagon, a 160-amino-acid precursor peptide encoded by the GCG gene. The same gene produces different peptide products depending on where it is expressed, a phenomenon called tissue-specific post-translational processing.
In pancreatic alpha cells, prohormone convertase 2 (PC2) cleaves proglucagon to release glucagon (amino acids 33-61), glicentin-related pancreatic polypeptide (GRPP), and a large fragment called major proglucagon fragment (MPGF).
In intestinal L-cells, prohormone convertase 1/3 (PC1/3) cleaves the same precursor differently, producing GLP-1 (glucagon-like peptide-1), GLP-2, oxyntomodulin, and glicentin. GLP-1 is the incretin hormone that forms the basis of semaglutide, liraglutide, and the broader class of GLP-1 receptor agonists.
Lafferty et al. (2021) reviewed the therapeutic implications of this shared ancestry in Frontiers in Endocrinology. They noted that understanding proglucagon processing has enabled the development of multi-receptor agonists that target glucagon, GLP-1, and GIP receptors simultaneously.[3] This is the molecular basis for drugs like tirzepatide and survodutide, which exploit the fact that these peptide systems evolved from the same precursor.
When the System Breaks: Type 1 vs Type 2 Diabetes
Type 1 Diabetes: Absolute Insulin Deficiency
Type 1 diabetes is an autoimmune destruction of beta cells. Without beta cells, there is no insulin production and no C-peptide release (which is why C-peptide measurement distinguishes type 1 from type 2). But alpha cells survive. The result is not simply "no insulin." It is a state where glucagon release becomes dysregulated because the normal intra-islet insulin signal that suppresses alpha cells is absent.
This creates glucose volatility. Without insulin, blood glucose rises uncontrolled after meals. Without proper glucagon suppression, the liver continues producing glucose even when blood levels are already high. And paradoxically, during hypoglycemia (from exogenous insulin therapy), the glucagon counter-regulatory response becomes blunted over time, removing the safety net against dangerously low blood sugar.
Dejgaard et al. (2024) tested liraglutide, a GLP-1 receptor agonist, in newly diagnosed type 1 diabetes patients. In a double-blind, placebo-controlled trial, liraglutide enhanced residual insulin secretion and prolonged the remission period. This finding suggests that GLP-1-mediated suppression of glucagon and support of remaining beta cell function may have value even in autoimmune diabetes.[4]
Type 2 Diabetes: Bihormonal Dysfunction
Type 2 diabetes involves insulin resistance (tissues respond poorly to insulin) combined with progressive beta cell failure (less insulin produced over time) and alpha cell dysregulation (inappropriate glucagon secretion). The three defects compound each other.
Modern peptide-based therapies target this from multiple angles. GLP-1 receptor agonists like semaglutide enhance glucose-dependent insulin secretion while suppressing inappropriate glucagon release. For an overview of the GLP-1 drug class, see the article on every GLP-1 receptor agonist compared.
Tirzepatide goes further by activating both GIP and GLP-1 receptors simultaneously. Frias (2020) reviewed the dual mechanism in Expert Review of Endocrinology & Metabolism, noting that the GIP component adds effects on beta cell function and fat metabolism that GLP-1 alone does not provide.[5] Popovic et al. (2024) reported that tirzepatide achieved normoglycemia (HbA1c below 5.7%, effectively diabetes remission) in 23.0% of trial participants with type 2 diabetes, raising questions about whether true disease remission through peptide therapy is achievable.[6] The article on how tirzepatide's dual mechanism differs covers this in detail.
Pieber et al. (2025) examined the counterregulatory response to hypoglycemia during tirzepatide treatment and found that the glucagon response to low blood sugar was preserved, an important safety finding since some diabetes drugs can blunt this protective mechanism.[7]
Beyond Insulin and Glucagon: The Supporting Cast
The pancreatic islets produce additional peptide hormones that fine-tune glucose regulation. Amylin (IAPP) is co-secreted with insulin from beta cells and slows gastric emptying, suppresses glucagon, and reduces food intake. Hay et al. (2015) reviewed amylin's pharmacology in Pharmacological Reviews, noting that pramlintide, a synthetic amylin analog, is the only FDA-approved amylin-based therapy for diabetes.[8] Boyle et al. (2018) further characterized amylin's role in both homeostatic and hedonic (reward-driven) eating control, suggesting it acts as a satiety signal at both metabolic and brain reward levels.[9]
Somatostatin from delta cells acts as a local brake on both insulin and glucagon secretion. Pancreatic polypeptide from PP cells regulates appetite and gastrointestinal motility. These hormones do not operate in isolation; they form a paracrine signaling network within the islet where each cell type influences its neighbors.
Ghrelin, produced primarily in the stomach, also modulates insulin-glucagon balance. Peng et al. (2012) demonstrated in The American Journal of the Medical Sciences that ghrelin inhibits insulin release by regulating inwardly rectifying potassium channel 6.2 (Kir6.2) expression in pancreatic islet cells. This provides a mechanism through which hunger signals directly influence the insulin-glucagon ratio.[10]
Emerging Dual and Triple Agonist Therapies
The discovery that glucagon, GLP-1, and GIP all derive from related precursor peptides has enabled a new generation of multi-receptor agonists.
Le Roux et al. (2024) published phase 2 trial results for survodutide, a glucagon and GLP-1 receptor dual agonist, in The Lancet Diabetes & Endocrinology. The drug produced dose-dependent weight loss of up to 14.9% at 46 weeks in people with obesity. The glucagon receptor component adds thermogenic effects (increased energy expenditure) that GLP-1 alone does not provide, though it also raises the theoretical risk of hyperglycemia from glucagon action.[11]
Kanbay et al. (2025) reviewed glucagon/GLP-1 dual agonism specifically for metabolic kidney disease, noting that glucagon receptor activation in the kidney promotes natriuresis and may offer renoprotective effects beyond what GLP-1 agonists achieve alone.[12]
Ferrannini et al. (2022) studied iGlarLixi, a fixed-ratio combination of insulin glargine plus lixisenatide (a GLP-1 agonist), demonstrating that combining insulin with GLP-1 receptor activation improved beta cell function markers beyond what either agent achieved alone. This approach essentially restores both sides of the insulin-glucagon equation simultaneously.[13]
The direction of the field is clear: rather than replacing a single missing hormone (as insulin therapy does), researchers are developing peptide-based interventions that address the full hormonal network. Whether this produces better long-term outcomes than insulin monotherapy remains under active investigation.
The Bottom Line
Insulin and glucagon are the two primary peptide hormones that maintain blood glucose within a survivable range. Their ratio, not their individual levels, determines whether the liver stores or releases glucose. Both type 1 and type 2 diabetes involve disruption of this balance from different causes. Modern peptide therapeutics, including GLP-1 agonists, dual GIP/GLP-1 agonists like tirzepatide, and glucagon/GLP-1 dual agonists like survodutide, attempt to restore normal hormonal signaling rather than simply replacing insulin.